U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H27NO
Molecular Weight 333.4666
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEPTROPINE

SMILES

CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC3C4=C(CCC5=C3C=CC=C5)C=CC=C4

InChI

InChIKey=ZWPODSUQWXAZNC-PMOLBWCYSA-N
InChI=1S/C23H27NO/c1-24-18-12-13-19(24)15-20(14-18)25-23-21-8-4-2-6-16(21)10-11-17-7-3-5-9-22(17)23/h2-9,18-20,23H,10-15H2,1H3/t18-,19+,20+

HIDE SMILES / InChI

Molecular Formula C23H27NO
Molecular Weight 333.4666
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Deptropine citrate is a well-known H1-histamine receptor antagonist and muscarinic receptor antagonist. It is prescribed frequently for treatment of asthma, although there has been a sharp decrease in prescriptions since 1994. Deptropine is gradually being replaced by inhaled beta 2 adrenergic agonists and glucocorticosteroids as the preferred clinical prescription. Recently deptropine has garnered interest as a potential treatment for breast cancer. In vitro studies have shown deptropine citrate has inhibitory effects on cell viability and mammosphere formation in Breast Cancer Stem Cells (BCSCs). However, it does not seem to inhibit the self-renewal capacity of the breast cancer cell line MDA-MB-231 when it is enriched with Cancer Stem Cells.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
aerosolized: 0.2 mg daily oral: 0.2 mg daily
Route of Administration: Other
In Vitro Use Guide
The ability to form mammospheres is correlated with the frequency of Cancer stem cells (CSCs) and progenitor cells in tumor cell lines. Thus, was analyzed the effects of different concentrations of deptropine citrate on mammosphere formation of MDA-MB-231 and 4T1-luc2 cells. In MDA-MB-231 cells, deptropine citrate reduced the size as well as the number of mammospheres significantly in a dose-dependent manner. The IC50 values of deptropine citrate for MDA-MB-231 spheres were 5 μM.
Substance Class Chemical
Record UNII
AY31301GKG
Record Status Validated (UNII)
Record Version